Predictive Risk Models to Identify Patients at High-Risk for Severe Clinical Outcomes With Chronic Kidney Disease and Type 2 Diabetes

Autor: Richard Sheer, Radhika Nair, Margaret K. Pasquale, Thomas Evers, Meghan Cockrell, Alain Gay, Rakesh Singh, Niklas Schmedt

Publikováno v: Journal of Primary Care & Community Health, Vol 13 (2022)

Introduction/Objective: Predictive risk models identifying patients at high risk for specific outcomes may provide valuable insights to providers and payers regarding points of intervention and modifiable factors. The goal of our study was to build p

Externí odkaz: https://doaj.org/article/ad63ed6a0af04f59b28d4bd8bb1aa408

Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study

Autor: Michael Blankenburg, Anne-Kathrin Fett, Seline Eisenring, Gabriele Haas, Alain Gay

Publikováno v: BMC Nephrology, Vol 20, Iss 1, Pp 1-14 (2019)

Abstract Background Steroidal mineralocorticoid receptor antagonists (MRAs) are recommended for the treatment of heart failure (HF) and resistant hypertension, both common comorbidities in patients with diabetes and chronic kidney disease (CKD). This

Externí odkaz: https://doaj.org/article/1ab0ff87c9614949b6981b2a3ae2100e

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE)

Autor: Jennifer B Green, Amy K Mottl, George Bakris, Hiddo J L Heerspink, Johannes F E Mann, Janet B McGill, Masaomi Nangaku, Peter Rossing, Charlie Scott, Alain Gay, Rajiv Agarwal

Publikováno v: Nephrology Dialysis Transplantation, 38(4):gfac198. Oxford University Press
Green, J B, Mottl, A K, Bakris, G, Heerspink, H J L, Mann, J F E, Mcgill, J B, Nangaku, M, Rossing, P, Scott, C, Gay, A & Agarwal, R 2023, ' Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) ', Nephrology Dialysis Transplantation, vol. 38, no. 4, pp. 894-903 . https://doi.org/10.1093/ndt/gfac198

BackgroundDespite available interventions, people with type 2 diabetes (T2D) remain at risk of chronic kidney disease (CKD). Finerenone, a potent and selective nonsteroidal mineralocorticoid receptor antagonist, and sodium–glucose cotransporter 2 i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76b5f3fc2d4f55a3cf493735484c8164
https://pubmed.ncbi.nlm.nih.gov/35700142

Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database

Autor: Kerstin Folkerts, Natalia Petruski-Ivleva, Erin Comerford, Michael Blankenburg, Thomas Evers, Alain Gay, Linda Fried, Csaba P. Kovesdy

Publikováno v: Mayo Clinic Proceedings. 96:975-986

Objective To examine the screening rates for kidney damage and function among patients with type 2 diabetes (T2D) and chronic kidney disease stage at diabetes diagnosis using a US administrative claims database. Patients and Methods This cohort study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf3ae278d561855248b6c1fd4c732efd
https://doi.org/10.1016/j.mayocp.2020.07.037

Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study

Autor: Csaba P Kovesdy, Danielle Isaman, Natalia Petruski-Ivleva, Linda Fried, Michael Blankenburg, Alain Gay, Priscilla Velentgas, Kerstin Folkerts

Publikováno v: Clinical Kidney Journal

Background Chronic kidney disease (CKD), one of the most common complications of type 2 diabetes (T2D), is associated with poor health outcomes and high healthcare expenditures. As the CKD population increases, a better understanding of the prevalenc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f98ae6360f9228a079f20350a9b5163
https://doi.org/10.1093/ckj/sfaa200